Tvardi Therapeutics, Inc.
TVRD
$27.66
$1.013.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 3.06M | 1.24M | 2.20M | 650.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 8.87M | 4.35M | 10.80M | 7.18M | |
| Operating Income | -8.87M | -4.35M | -10.80M | -7.18M | |
| Income Before Tax | 4.17M | -9.58M | -12.71M | -6.98M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 4.17M | -9.58M | -12.71M | -6.98M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 4.17M | -9.58M | -12.71M | -6.98M | |
| EBIT | -8.87M | -4.35M | -10.80M | -7.18M | |
| EBITDA | -8.85M | -4.33M | -10.78M | -7.16M | |
| EPS Basic | 0.51 | -1.50 | -1.99 | -2.71 | |
| Normalized Basic EPS | 0.32 | -0.94 | -1.24 | -1.69 | |
| EPS Diluted | -1.00 | -1.50 | -1.99 | -2.71 | |
| Normalized Diluted EPS | 0.31 | -0.94 | -1.24 | -1.69 | |
| Average Basic Shares Outstanding | 8.25M | 6.40M | 6.40M | 2.57M | |
| Average Diluted Shares Outstanding | 8.46M | 6.40M | 6.40M | 2.57M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |